

ARG70027 anti-RIPK1 / RIP1 antibody [7H10]

Package: 50 μl Store at: -20°C

Summary

Product Description	Mouse Monoclonal antibody [7H10] recognizes RIPK1 / RIP1
Tested Reactivity	Hu, Ms, Rat
Tested Application	IHC-P, IP, WB
Host	Mouse
Clonality	Monoclonal
Clone	7H10
Isotype	lgG2b, kappa
Target Name	RIPK1 / RIP1
Species	Human
Immunogen	Recombinant Human His/ABD-RIP1 protein purified from E. coli.
Conjugation	Un-conjugated
Alternate Names	Receptor-interacting protein 1; RIP-1; Receptor-interacting serine/threonine-protein kinase 1; RIP; Cell death protein RIP; RIP1; EC 2.7.11.1; Serine/threonine-protein kinase RIP

Application Instructions


Application table	Application	Dilution
	IHC-P	Assay-dependent
	IP	Assay-dependent
	WB	1:500 - 1:2000
Application Note	* The dilutions indicate recomm should be determined by the sc	nended starting dilutions and the optimal dilutions or concentrations ientist.
Positive Control	HeLa	
Observed Size	~ 78 kDa	

Properties

Form	Liquid
Purification	Purification with Protein G.
Buffer	HEPES, 0.15M NaCl, 0.03% Sodium azide, 50% Glycerol and 0.01% BSA.
Preservative	0.03% Sodium azide
Stabilizer	50% Glycerol and 0.01% BSA
Concentration	1 mg/ml


Bioinformation

Diointornation	
Gene Symbol	RIPK1
Gene Full Name	receptor (TNFRSF)-interacting serine-threonine kinase 1
Background	RIPK1 / RIP1 is a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases. The encoded protein plays a role in inflammation and cell death in response to tissue damage, pathogen recognition, and as part of developmental regulation. RIPK1/RIPK3 kinase-mediated necrosis is referred to as necroptosis. Genetic disruption of this gene in mice results in death shortly after birth. [provided by RefSeq, Aug 2017]
Function	RIPK1 / RIP1: Serine-threonine kinase which is a key regulator of both cell death and cell survival (PubMed:25459879). Exhibits kinase activity-dependent functions that trigger cell death and kinase- independent scaffold functions regulating inflammatory signaling and cell survival (PubMed:11101870, PubMed:25459879). Initiates ripoptocide which describes cell death that is dependent on RIPK1, be it apoptosis or necroptosis (PubMed:31457011). Upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kB pathway. Specific conditions can however activate RIPK1, and its kinase activity then regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8) and the complex IIb (RIPK1-RIPK3-MLKL) and these complexes respectively drive apoptosis or necroptosis, a regulated form of necrosis (PubMed:19524513, PubMed:19524512, PubMed:29440439, PubMed:30988283). During embryonic development suppresses apoptosis and necroptosis and prevents the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8. Phosphorylates DAB2IP at 'Ser-728' in a TNF- alpha- dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:17389591). Required for ZBP1-induced NF-kappaB activation and activation of NF-kappaB by DNA damage and IR. [UniProt]
Highlight	Related products: <u>RIPK1 antibodies; RIPK1 Duos / Panels; Anti-Mouse IgG secondary antibodies;</u> Related news: <u>RIP1 activation and pathogenesis of NASH</u> <u>Ripoptosome & Necrosome antibody panels are launched</u>
Calculated Mw	76 kDa
РТМ	Proteolytically cleaved by caspase-8 during TNF-induced apoptosis. Cleavage abolishes NF-kappa-B activation and enhances pro-apoptotic signaling through the TRADD-FADD interaction.
	RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation. Phosphorylation of Ser-161 by RIPK3 is necessary for the formation of the necroptosis-inducing complex.
	Ubiquitinated by 'Lys-11'-, 'Lys-48'-, 'Lys-63'- and linear-linked type ubiquitin. Polyubiquitination with 'Lys-63'-linked chains by TRAF2 induces association with the IKK complex. Deubiquitination of 'Lys-63'-linked chains and polyubiquitination with 'Lys-48'-linked chains by TNFAIP3 leads to RIPK1 proteasomal degradation and consequently down-regulates TNF-alpha-induced NFkappa-B signaling. 'Lys-48'-linked polyubiquitination by RFFL or RNF34 also promotes proteasomal degradation and negatively regulates TNF-alpha-induced NFkappa-B signaling. Linear polyubiquitinated; the head-to-tail polyubiquitination is mediated by the LUBAC complex. LPS-mediated activation of NF-kappa-B. Also ubiquitinated with 'Lys-11'-linked chains. Polyubiquitinated with 'Lys-48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B. [UniProt]
Cellular Localization	Cytoplasm. Cell membrane. [UniProt]



ARG70027 anti-RIPK1 / RIP1 antibody [7H10] WB image

Western blot: K562, HeLa and SK-N-MC cell lysates stained with ARG70027 anti-RIPK1 / RIP1 antibody [7H10] at 0.5 $\mu g/ml$ dilution, overnight at 4°C.



ARG70027 anti-RIPK1 / RIP1 antibody [7H10] IP-WB image

Immunoprecipitation-Western blot: HeLa cell lysate as input control (Lane 1); 200µg of HeLa cell lysate immunoprecipitated by ARG70027 anti-RIPK1 / RIP1 antibody [7H10] at 2 µg (Lane 2) or 5 µg (Lane 3); PBS control sample immunoprecipitated by ARG70027 at 5 µg (Lane 4). The blots were then stained with ARG70027 anti-RIPK1 / RIP1 antibody [7H10] at 1 µg/ml and incubated for overnight at 4°C.